Nordea Investment Management AB Makes Strategic Acquisition in United Therapeutics Co.
July 13, 2023
☀️Trending News
Nordea Investment Management AB, one of the largest institutional investors in the world, has recently made a strategic acquisition in United Therapeutics ($NASDAQ:UTHR) Co. United Therapeutics is a biotechnology company that develops novel treatments for chronic and life-threatening diseases. The company’s mission is to develop therapeutics that improve patient outcomes and reduce the cost of healthcare. Since its founding, United Therapeutics’ stock has been one of the best performers in the market.
This is primarily due to the fact that the company has consistently delivered strong financial performance and innovative products. The company has also forged strategic partnerships with numerous other entities to further expand its network and market share.
Share Price
On Monday, Nordea Investment Management AB made a strategic acquisition in United Therapeutics Corporation (UNITED THERAPEUTICS). This announcement caused UNITED THERAPEUTICS stock to rise 5.3% from the previous day’s closing price of $211.6 to close at $223.1. This significant increase in share price demonstrates investors’ confidence in the potential of the company. Nordea Investment Management AB is a Swedish-based, independent asset management firm with a long-term focus on investing in innovative companies.
As such, their decision to invest in United Therapeutics speaks to the potential that they believe UNITED THERAPEUTICS has to offer. Moving forward, it will be interesting to see how this move by Nordea Investment Management AB affects the future of UNITED THERAPEUTICS. It is clear that the company has a promising future ahead and with this new partnership, promising things are in store for both parties. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for United Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 1.98k | 728.3 | 36.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for United Therapeutics. More…
| Operations | Investing | Financing |
| 888.6 | -673.4 | 135 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for United Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.35k | 1.22k | 109.71 |
Key Ratios Snapshot
Some of the financial key ratios for United Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 11.2% | 15.4% | 49.2% |
| FCF Margin | ROE | ROA |
| 36.4% | 12.3% | 9.6% |
Analysis
At GoodWhale, we have conducted an analysis of UNITED THERAPEUTICS‘s fundamentals. Our Star Chart reveals that UNITED THERAPEUTICS has a high health score of 9/10 with regard to its cashflows and debt, indicating that the company is well-positioned to sustain operations in times of crisis. In addition, UNITED THERAPEUTICS is strong in asset, profitability, and medium in growth. On the other hand, UNITED THERAPEUTICS is weak in dividend. Based on our assessment, we classify UNITED THERAPEUTICS as ‘gorilla’, a type of company we conclude that achieved stable and high revenue or earning growth due to its strong competitive advantage. As a ‘gorilla’ company, UNITED THERAPEUTICS could be attractive to value investors looking for stability and sustainability, growth investors looking for healthy returns, and dividend investors seeking out a reliable dividend yield. Given the company’s strong fundamentals and competitive advantages, UNITED THERAPEUTICS is an attractive option for all types of investors, and may be especially appealing to those looking for a mix of growth and stability. More…
Peers
The company’s main competitors are MannKind Corp, Sanofi SA, Eli Lilly and Co.
– MannKind Corp ($NASDAQ:MNKD)
MannKind Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics for diabetes and cancer. Its product pipeline includes Afrezza, MK-1293, and MK-3655. The company was founded by Alfred E. Mann on February 3, 1991 and is headquartered in Valencia, CA.
– Sanofi SA ($OTCPK:SNYNF)
Sanofi has a market cap of 98.97B as of 2022 and a Return on Equity of 7.56%. The company is a French multinational pharmaceutical company headquartered in Paris, France, and was founded in 1904. Sanofi is engaged in the research, development, manufacturing, and marketing of pharmaceutical products for the treatment of patients in the areas of cardiovascular, central nervous system, diabetes, internal medicine, oncology, and thrombosis.
– Eli Lilly and Co ($NYSE:LLY)
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
The company’s market cap is $312.67 billion as of 2022 and its return on equity is 45.88%.
Summary
Nordea Investment Management AB recently acquired shares in United Therapeutics Co., causing the company’s stock price to move up the same day. This reflects the investor confidence in the company, which could be due to the company’s strong financial performance or potential for future growth. Analyzing United Therapeutics’ performance and potential can help investors decide whether the stock is a good investment.
An analysis should include evaluating the company’s cash flow, debt levels, competitive position, and future prospects. By considering all of these aspects, investors can make an informed decision when it comes to investing in United Therapeutics.
Related Posts
Recent Posts
